TP53 target 3 family member H, pseudogeneGenealiases: []
Q-omics provides the consensus-scored TP53TG3HP profile across patient tissues and cancer cell-line models. TP53TG3HP expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TP53TG3HP is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, TP53TG3HP RNA expression shows 12,021 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, HNSC, and TGCT as cancer lineages where TP53TG3HP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53TG3HP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53TG3HP survival associations across molecular data types. TP53TG3HP RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53TG3HP RNA expression–survival associations across cancer types. High TP53TG3HP expression shows unfavorable associations in KICH, ESCA, COAD, LUAD and STAD, but favorable associations in SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TP53TG3HP RNA expression.
This table summarizes TP53TG3HP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TP53TG3HP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53TG3HP shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher TP53TG3HP RNA expression in tumor versus normal tissue (log2 FC = +0.013, t-test p = .023).
This table shows molecular features associated with TP53TG3HP in patient tissues and cancer cell lines. In patient samples, TP53TG3HP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
